Five-Year EU Benefit-Risk Project Bearing Fruit, Says EMA
This article was originally published in SRA
Executive Summary
In what can be seen as an example of the benefits of EU-wide research projects in the life science area, the European Medicines Agency says that the public-private PROTECT project, which ran for five years from late 2009 to early 2015, is already making a difference in the way that companies and regulators measure the benefits and risks of marketed medicines1.